Cambridge-based Evonetix, a synthetic biology company that brings semiconductor technology to DNA synthesis, announced on Tuesday, February 7, that it has raised an additional $24M (approximately €22.36M) to bring its total Series B funding round to $54M.
The round was led by existing investor Foresite Capital. Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures, and Providence also participated in the round.
Jim Tananbaum, Founder and CEO at Foresite Capital, says, “We continue to be impressed by the Evonetix team and technology, and are excited to lead this round to accelerate their commercial strategy and make gene synthesis more accessible.”
Founded in 2015 by Matthew Hayes and currently led by CEO Colin McCracken, Evonetix claims to reimage biology by developing a different approach to gene synthesis – a highly parallel desktop platform to synthesise DNA with better accuracy and scale.